Find TTC-352 manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Ttc-352, 1607819-68-0, 65ilh3y0mi, Chembl3763743, 3-(4-fluorophenyl)-2-(4-hydroxyphenoxy)-1-benzothiophene-6-ol, 3-(4-fluorophenyl)-2-(4-hydroxyphenoxy)-benzo[b]thiophene-6-ol
Molecular Formula
C20H13FO3S
Molecular Weight
352.4  g/mol
InChI Key
UDBMVVLTKJMPCJ-UHFFFAOYSA-N
FDA UNII
65ILH3Y0MI

TTC-352
Selective Human Estrogen-receptor Alpha Partial Agonist TTC-352 is a benzothiophene and orally bioavailable selective human estrogen receptor alpha (ERalpha; ESR1; ERa) partial agonist (ShERPA), with potential antineoplastic activity. Upon administration, TTC-352 mimics the naturally-occurring 17beta-estradiol (E2) and targets and binds to ERa located in the nucleus. This causes translocation of ERa to extranuclear sites. Nuclear export of ERa prevents normal ER-mediated signaling and inhibits proliferation of ER-positive tumor cells. TTC-352 causes tumor regression of tamoxifen (TAM)-resistant (TR) tumor cells which often overexpress protein kinase C alpha (PKCalpha; PKCa). PKCa expression is associated with poor patient survival and breast cancer aggressiveness and may predict tumor responses to E2, E2-like compounds and ShERPAs. Unlike E2 and E2-like compounds, TTC-352 does not cause endometrial proliferation.
1 2D Structure

TTC-352

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
3-(4-fluorophenyl)-2-(4-hydroxyphenoxy)-1-benzothiophen-6-ol
2.1.2 InChI
InChI=1S/C20H13FO3S/c21-13-3-1-12(2-4-13)19-17-10-7-15(23)11-18(17)25-20(19)24-16-8-5-14(22)6-9-16/h1-11,22-23H
2.1.3 InChI Key
UDBMVVLTKJMPCJ-UHFFFAOYSA-N
2.1.4 Canonical SMILES
C1=CC(=CC=C1C2=C(SC3=C2C=CC(=C3)O)OC4=CC=C(C=C4)O)F
2.2 Other Identifiers
2.2.1 UNII
65ILH3Y0MI
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. Ttc-352

2. 1607819-68-0

3. 65ilh3y0mi

4. Chembl3763743

5. 3-(4-fluorophenyl)-2-(4-hydroxyphenoxy)-1-benzothiophene-6-ol

6. 3-(4-fluorophenyl)-2-(4-hydroxyphenoxy)-benzo[b]thiophene-6-ol

7. 3-(4-fluorophenyl)-2-(4-hydroxyphenoxy)benzo(b)thiophene-6-ol

8. Selective Human Estrogen-receptor Alpha Partial Agonist Ttc-352

9. Benzo(b)thiophene-6-ol, 3-(4-fluorophenyl)-2-(4-hydroxyphenoxy)-

10. Unii-65ilh3y0mi

11. Schembl15658409

12. Bdbm50145856

13. J3.603.123i

14. 2-(4-hydroxyphenoxy)-3-(4-fluorophenyl)benzo[b]thiophene-6-ol

15. 3-(4-fluorophenyl)-2-(4-hydroxyphenoxy)-1-benzothiophen-6-ol

16. 3-(4-fluorophenyl)-2-(4-hydroxyphenoxy)benzo[b]thiophen-6-ol

17. 3-(4-fluorophenyl)-2-(4-hydroxyphenoxyl)benzo[b]thiophen-6-ol

18. V9j

2.4 Create Date
2014-06-09
3 Chemical and Physical Properties
Molecular Weight 352.4 g/mol
Molecular Formula C20H13FO3S
XLogP35.8
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count5
Rotatable Bond Count3
Exact Mass352.05694361 g/mol
Monoisotopic Mass352.05694361 g/mol
Topological Polar Surface Area77.9 Ų
Heavy Atom Count25
Formal Charge0
Complexity435
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty